Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 39

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 39
---
 (8)                                            |     |                    |    245,088 |     | *                  |      |   |
| Peter Hirth, Ph.D.(9)                                            |     |                    |    249,490 |     | *                  |      |   |
| Kathleen Sereda Glaub, M.B.A.(10)                                |     |                    |    207,770 |     | *                  |      |   |
| David V. Smith, M.B.A.(11)                                       |     |                    |    139,079 |     | *                  |      |   |
| Christian Elling, Ph.D.(1,12)                                    |     |                    |    111,060 |     | *                  |      |   |
| Heidi Hunter(13)                                                 |     |                    |     83,114 |     | *                  |      |   |
| Helen Collins, M.D. (14)                                         |     |                    |     77,761 |     | *                  |      |   |
| All directors and executive officers as a group (10 persons)(15) |     |                    |  3,133,852 |     |                    |  4.8 | % |

* Indicates beneficial ownership of less than 1% of the outstanding shares of our common stock. (1) Based solely on a Schedule 13D/A filed on August 14, 2023 by Lundbeckfond Invest A/S reporting sole voting and dispositive power over 21,851,920 shares. Christian Elling, a member of our board of directors, is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S. Dr. Elling disclaims beneficial ownership of the shares held by Lundbeckfond Invest A/S except to the extent of his pecuniary interest therein. The principal business address of Lundbeckfond Invest A/S is Scherfigsvej 7, DK-2100 Copenhagen Ø, Denmark.

<div align='center'>30</div>

Based solely on a Schedule 13G filed on September 7, 2023 by Kurma Partners reporting sole voting and dispositive power over 12,253,230 shares. The principal business address of Kurma Partners is 24 Rue Royale, Paris, France 75008.

Based solely on a Form 4 filed on August 10, 2023 by Vivo Capital IX, LLC, reporting sole voting and dispositive power